{"id":1017677,"date":"2026-11-05T11:18:02","date_gmt":"2026-11-05T16:18:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/grace-therapeutics-announces-participation-in-upcoming-industry-and-investor-events-in-november-2026\/"},"modified":"2026-11-05T11:18:02","modified_gmt":"2026-11-05T16:18:02","slug":"grace-therapeutics-announces-participation-in-upcoming-industry-and-investor-events-in-november-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/grace-therapeutics-announces-participation-in-upcoming-industry-and-investor-events-in-november-2026\/","title":{"rendered":"Grace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">PRINCETON, N.J., Nov.  05, 2026  (GLOBE NEWSWIRE) &#8212; Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the Company\u2019s participation in upcoming healthcare industry and investor conferences during the month of November.<\/p>\n<p align=\"justify\">Chief Executive Officer Prashant Kohli will be meeting with industry representatives and investors at the following events. \u00a0<\/p>\n<p align=\"justify\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OTi6AWV0YVQbDp-Aq4wFGCjVntukovgC1eCuiCinnZ3XF3uwr9zgnv8DXjP1JYtXl5HNMW1TKdjiRavpHDoCuz9qwWbqHr-4m7sqKE3pvR7BqDqdMd_e37Aj_9unD_6NVpRIdFUHStDed0NJQBULxirqY7f1_JypZosv5R44KEO51DiFJ43L0xPkVFLEfDfp3pjLoeSFTYf7JHSYe3-2m9elywTgmd-RGjycqXpVm9kGVuGAZUbDpe9Su7SfHhlDfKohpIehXyuc6a_U8A97O6fJxoQamto1vXeBQHYVDeDCfGXj6flL0Obks5mGZgS5umzhtEpyaSdjTy_hCF2MI8UUtB8U0dJ8JWXRa2G7wLJxIaXHJ_wCaP76m7U9uwUWtJUTJG_SK_cax-qZMJYXselI3Cf-Br6URih648wrw-VXtZZmYCbhVthP3si9hkyerUTauP2cSc3eoEP9ayc3R5c-JzmII0w827wU-3chB3H35Cg_xzcJoda9iWLhNbYY_tQNvUM0iPm2pMha-zF5wQPVwajqNKYrPswJIbiRHWc=\" rel=\"nofollow\" target=\"_blank\">BIO-Europe 2026 | Global Biopharma Partnering Event | Cologne, Germany<\/a><br \/>\n        <br \/>November 9-11, 2026<br \/>Cologne, Germany<\/p>\n<p align=\"justify\">BIO-Europe is a global biopharma partnering event, bringing together industry leaders, innovators, and decision-makers from across the life sciences ecosystem. For over three decades, BIO-Europe has served as the premier platform for forging strategic partnerships, advancing groundbreaking collaborations, and driving the future of biopharma innovation.<\/p>\n<p align=\"justify\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4WhQGMqz7U2q2G4OLvRotB3_r9Lz_rgp-kq5x2AS6pTspUkp-Vr3k2Z4ywWm_CqFkWgnWmX7GTU92m7-OmgorMGuEkJ-kkF81b7yvlEKO32rc6iHaun0Wk3Jc5YDyNhuk-RxA_ZK4PKHHHiKEQqbVA==\" rel=\"nofollow\" target=\"_blank\">Craig-Hallum 17<\/a><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UNU3Df55J7vnuJ7fZAxcrSh1tZ6M_wUdp7c_9LIV6uz9NkVDGnzE97hiO8a7YsXgjutU4tUbidaFh1fxFgr7OvlSz-f_SjAKox9EtH4FAqIH3TGxDN9IB-69yQHG-ONU\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <sup>th<\/sup><br \/>\n        <\/a><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yMVsQKxyGnPO8_9PjOaBFdRt3aKvbOEqiNjCHrPeZBqPpb2e4UFUkAiHLzTTh-nfoI4Q2oAOXMIQ6M5m--2O5jN44wf04KliaNyMK0ckyocPtvg6CpK6W31Xx7st0zzxUbfuX9rTogR-jZJG1s7M-aS2TUMu_xe5pCT5gkd1ynQ=\" rel=\"nofollow\" target=\"_blank\"> Annual Alpha Select Conference<\/a><br \/>\n        <br \/>Tuesday, November 17 2026<br \/>New York, NY<\/p>\n<p align=\"justify\">Registration for the Craig-Hallum conference is by invitation only. Contact your Craig-Hallum representative for more information.\u00a0<\/p>\n<p>\n        <strong>About Grace Therapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">Grace Therapeutics, Inc. (Grace Therapeutics or the Company) is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Grace Therapeutics\u2019 novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery. Grace Therapeutics\u2019 lead clinical asset, GTx-104, is an IV infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. GTx-104 has been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States if certain conditions are met at NDA approval, and additional intellectual property protection with 52 granted and pending patents.<\/p>\n<p>\n        <strong>For more information, please visit: <\/strong><br \/>\n        <strong><br \/>\n          <u>www.gracetx.com.<\/u><br \/>\n        <\/strong>\n      <\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">Statements in this press release that are not statements of historical or current fact constitute \u201cforward-looking statements\u201d within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and \u201cforward-looking information\u201d within the meaning of Canadian securities laws (collectively, \u201cforward-looking statements\u201d). Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Grace Therapeutics to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements containing the terms \u201cbelieves,\u201d \u201cbelief,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201canticipates,\u201d \u201cestimates,\u201d \u201cpotential,\u201d \u201cshould,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cplans,\u201d \u201ccontinue,\u201d \u201ctargeted\u201d or other similar expressions to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The forward-looking statements in this press release, including statements regarding the Company\u2019s cash runway; future prospects of the Company\u2019s GTx-104 drug candidate; the Company\u2019s belief that the issues identified by the FDA in the CRL can be successfully addressed in the Company\u2019s resubmission of the NDA for GTx-104; the Company\u2019s planned approach to addressing the items cited in the CRL following its Type A meeting with the FDA and receipt of the official meeting minutes; the Company\u2019s dual source manufacturing strategy, including remediation at its current contract manufacturer and technology transfer to a second, U.S.-based contract manufacturer; the timing and outcome of any FDA reinspection of the current contract manufacturer; the Company\u2019s plans to complete the required non-clinical studies; and the Company\u2019s plans to report progress against key milestones; GTx-104\u2019s potential to bring enhanced treatment options to patients suffering from aSAH; the ability of GTx-104 to potentially eliminate the need for nasogastric tube administration in unconscious or dysphagic patients; the potential of GTx-104 to lower food effects, drug-to-drug interactions, and to eliminate potential dosing errors; the potential of GTx-104 to better manage hypotension in aSAH patients; and the Company\u2019s intellectual property estate for GTx-104, are based upon Grace Therapeutics\u2019 current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: (i) the timing and success of any regulatory resubmission of the NDA for GTx-104; (ii) the timing of any FDA reinspection of the Company\u2019s current contract manufacturer, and that facility\u2019s compliance status, which are determined by the FDA and outside the Company\u2019s control, and the FDA\u2019s position that it will not approve the NDA while the facility remains in an unacceptable compliance status; (iii) the ability of a second, U.S.-based contract manufacturer to generate the required stability and analytical data and to complete a product-specific pre-approval inspection; (iv) the need to complete additional non-clinical studies; (v) the requirement that any resubmission comprehensively address all items cited in the CRL and the risk of review delay; (vi) the Company\u2019s potential need for additional capital, which may not be available on acceptable terms; (vii) changes to regulatory pathways; (viii) the Company\u2019s ability to protect its intellectual property for GTx-104; and (ix) legislative, regulatory, political and economic developments. The foregoing list of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors detailed in the \u201cSpecial Note Regarding Forward-Looking Statements,\u201d \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations\u201d sections of the Company\u2019s Annual Report on Form 10-K for the fiscal year ended March 31, 2026 filed with the Securities and Exchange Commission (SEC) and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC and other documents that have been and will be filed by Grace Therapeutics from time to time with the SEC and Canadian securities regulators. All forward-looking statements contained in this press release speak only as of the date on which they were made. Grace Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by applicable securities laws.<\/p>\n<p>For more information, please contact:<\/p>\n<p>\n        <strong>Grace Therapeutics Contact: \u00a0 \u00a0<\/strong><br \/>\n        <br \/>\u00a0 \u00a0\u00a0<br \/>Prashant Kohli \u00a0 \u00a0<br \/>Chief Executive Officer \u00a0 \u00a0<br \/>Tel: 609-322-1602 \u00a0 \u00a0<br \/>Email: info@gracetx.com \u00a0 \u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=f31gDGsv-eenykG9QcvFgml3UZY9THnQTm_9IsArckreRy67tezeoXvlPA5EvbLVbI7OJ8tLlvLt913TGa4Ijae06iuwFVnUCdByDOgXgs4=\" rel=\"nofollow\" target=\"_blank\">www.gracetx.com<\/a> \u00a0 \u00a0<br \/>\u00a0 \u00a0\u00a0<br \/><strong>Investor Relations: \u00a0 \u00a0<\/strong><br \/>\u00a0 \u00a0\u00a0<br \/>LifeSci Advisors \u00a0 \u00a0<br \/>Mike Moyer \u00a0 \u00a0<br \/>Managing Director \u00a0 \u00a0<br \/><strong>Phone<\/strong>: 617-308-4306 \u00a0 \u00a0<br \/><strong>Email<\/strong>: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fgyvYVc9kGJ377om0EL-eTIEd_gYicF_4V_4fMMt_Ej4b2EaDF-N6Ji2xM0vNaX8Bzbj0ifuvpTW7zp3zpkrqyrgAXXTjuTpDq8tNSdVo4_XEu4A3veEAqsg21AZXpEu\" rel=\"nofollow\" target=\"_blank\">mmoyer@lifesciadvisors.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MDUxOCM3OTQ1Njk4IzUwMDExNzkyNw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NDA4NmYxZDktYTQ5Mi00NGNhLWJjNTItOTY1Zjk4YzJjZDc4LTUwMDExNzkyNy0yMDI2LTExLTA1LWVu\/tiny\/Grace-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) &#8212; Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the Company\u2019s participation in upcoming healthcare industry and investor conferences during the month of November. Chief Executive Officer Prashant Kohli will be meeting with industry representatives and investors at the following events. \u00a0 BIO-Europe 2026 | Global Biopharma Partnering Event | Cologne, Germany November 9-11, 2026Cologne, Germany BIO-Europe is a global biopharma partnering event, bringing together industry leaders, innovators, and decision-makers from across the life sciences ecosystem. For over three decades, BIO-Europe has &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/grace-therapeutics-announces-participation-in-upcoming-industry-and-investor-events-in-november-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Grace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1017677","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Grace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/grace-therapeutics-announces-participation-in-upcoming-industry-and-investor-events-in-november-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Grace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) &#8212; Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the Company\u2019s participation in upcoming healthcare industry and investor conferences during the month of November. Chief Executive Officer Prashant Kohli will be meeting with industry representatives and investors at the following events. \u00a0 BIO-Europe 2026 | Global Biopharma Partnering Event | Cologne, Germany November 9-11, 2026Cologne, Germany BIO-Europe is a global biopharma partnering event, bringing together industry leaders, innovators, and decision-makers from across the life sciences ecosystem. For over three decades, BIO-Europe has &hellip; Continue reading &quot;Grace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/grace-therapeutics-announces-participation-in-upcoming-industry-and-investor-events-in-november-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-05T16:18:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MDUxOCM3OTQ1Njk4IzUwMDExNzkyNw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/grace-therapeutics-announces-participation-in-upcoming-industry-and-investor-events-in-november-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/grace-therapeutics-announces-participation-in-upcoming-industry-and-investor-events-in-november-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Grace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026\",\"datePublished\":\"2026-11-05T16:18:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/grace-therapeutics-announces-participation-in-upcoming-industry-and-investor-events-in-november-2026\\\/\"},\"wordCount\":1124,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/grace-therapeutics-announces-participation-in-upcoming-industry-and-investor-events-in-november-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MDUxOCM3OTQ1Njk4IzUwMDExNzkyNw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/grace-therapeutics-announces-participation-in-upcoming-industry-and-investor-events-in-november-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/grace-therapeutics-announces-participation-in-upcoming-industry-and-investor-events-in-november-2026\\\/\",\"name\":\"Grace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/grace-therapeutics-announces-participation-in-upcoming-industry-and-investor-events-in-november-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/grace-therapeutics-announces-participation-in-upcoming-industry-and-investor-events-in-november-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MDUxOCM3OTQ1Njk4IzUwMDExNzkyNw==\",\"datePublished\":\"2026-11-05T16:18:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/grace-therapeutics-announces-participation-in-upcoming-industry-and-investor-events-in-november-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/grace-therapeutics-announces-participation-in-upcoming-industry-and-investor-events-in-november-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/grace-therapeutics-announces-participation-in-upcoming-industry-and-investor-events-in-november-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MDUxOCM3OTQ1Njk4IzUwMDExNzkyNw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MDUxOCM3OTQ1Njk4IzUwMDExNzkyNw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/grace-therapeutics-announces-participation-in-upcoming-industry-and-investor-events-in-november-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Grace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Grace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/grace-therapeutics-announces-participation-in-upcoming-industry-and-investor-events-in-november-2026\/","og_locale":"en_US","og_type":"article","og_title":"Grace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026 - Market Newsdesk","og_description":"PRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) &#8212; Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the Company\u2019s participation in upcoming healthcare industry and investor conferences during the month of November. Chief Executive Officer Prashant Kohli will be meeting with industry representatives and investors at the following events. \u00a0 BIO-Europe 2026 | Global Biopharma Partnering Event | Cologne, Germany November 9-11, 2026Cologne, Germany BIO-Europe is a global biopharma partnering event, bringing together industry leaders, innovators, and decision-makers from across the life sciences ecosystem. For over three decades, BIO-Europe has &hellip; Continue reading \"Grace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/grace-therapeutics-announces-participation-in-upcoming-industry-and-investor-events-in-november-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-05T16:18:02+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MDUxOCM3OTQ1Njk4IzUwMDExNzkyNw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/grace-therapeutics-announces-participation-in-upcoming-industry-and-investor-events-in-november-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/grace-therapeutics-announces-participation-in-upcoming-industry-and-investor-events-in-november-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Grace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026","datePublished":"2026-11-05T16:18:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/grace-therapeutics-announces-participation-in-upcoming-industry-and-investor-events-in-november-2026\/"},"wordCount":1124,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/grace-therapeutics-announces-participation-in-upcoming-industry-and-investor-events-in-november-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MDUxOCM3OTQ1Njk4IzUwMDExNzkyNw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/grace-therapeutics-announces-participation-in-upcoming-industry-and-investor-events-in-november-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/grace-therapeutics-announces-participation-in-upcoming-industry-and-investor-events-in-november-2026\/","name":"Grace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/grace-therapeutics-announces-participation-in-upcoming-industry-and-investor-events-in-november-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/grace-therapeutics-announces-participation-in-upcoming-industry-and-investor-events-in-november-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MDUxOCM3OTQ1Njk4IzUwMDExNzkyNw==","datePublished":"2026-11-05T16:18:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/grace-therapeutics-announces-participation-in-upcoming-industry-and-investor-events-in-november-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/grace-therapeutics-announces-participation-in-upcoming-industry-and-investor-events-in-november-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/grace-therapeutics-announces-participation-in-upcoming-industry-and-investor-events-in-november-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MDUxOCM3OTQ1Njk4IzUwMDExNzkyNw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MDUxOCM3OTQ1Njk4IzUwMDExNzkyNw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/grace-therapeutics-announces-participation-in-upcoming-industry-and-investor-events-in-november-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Grace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1017677","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1017677"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1017677\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1017677"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1017677"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1017677"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}